ANAPC11 and melanoma: Furthermore, the combination of anti-PD1 antibodies with PEG-TAT-APC11 or NP-APC11 demonstrated synergistic anti-tumor effects in APC-mutant CRC, which is typically resistant to anti-PD1 therapy, as well as in melanoma and breast cancer models.